Alan H. Fairlamb

发表

TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei

Rainer Breitling, Michael P. Barrett, Ludovic Cottret, 2014, Nucleic Acids Res..

Trypanothione reductase from Trypanosoma cruzi

Alan H. Fairlamb, A. Fairlamb, R. Schirmer, 1987 .

Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography

Ian H. Gilbert, Alan H. Fairlamb, Paul G. Wyatt, 2011, Journal of medicinal chemistry.

N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness

Ian H. Gilbert, Chidochangu P. Mpamhanga, Michael Hodgkinson, 2010, Nature.

Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors

David S. Wishart, Rolando Perez-Pineiro, Alan H. Fairlamb, 2009, Journal of medicinal chemistry.

One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening

Ian H. Gilbert, Chidochangu P. Mpamhanga, William N. Hunter, 2009, Journal of medicinal chemistry.

Erratum: Phenothiazine inhibitors of trypanothione reductase as potenial antitrypanosomal and antileishmanial drugs (Journal of Medicinal Chemistry (1998) 41 (150))

Kenneth T. Douglas, Alan H. Fairlamb, Simon L. Croft, 1998 .

Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

Ian H. Gilbert, Irene Hallyburton, Alan H. Fairlamb, 2011, Journal of medicinal chemistry.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Ian H. Gilbert, David Horn, Mark C. Field, 2017, Nature Reviews Microbiology.

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

Irene Hallyburton, Alan H. Fairlamb, L. Stojanovski, 2010, Biochemical pharmacology.